Trials that use: P-values
New to this method? Read the tutorial →
389 results
- ODINIndependent statistical analysis of the ODIN phase 3 trial comparing once-daily versus twice-daily darunavir/ritonavir in early treatment-experienced HIV-1 infected patients, including non-inferiority methodology, logistic regression, ANCOVA, Cox models, confidence intervals, and reported…
- ODYSSEY OUTCOMESComplete statistical analysis of ODYSSEY OUTCOMES, the randomized phase 3 trial of alirocumab versus placebo after acute coronary syndrome, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, safety, and statistical interpretation.
- OlympiAComplete statistical analysis of the OlympiA phase 3 trial of adjuvant olaparib versus placebo in patients with germline BRCA-mutated high-risk HER2-negative primary breast cancer, including trial design, time-to-event endpoints, statistical methods, reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- OPUSIndependent statistical analysis of the OPUS trial of cetuximab plus FOLFOX-4 versus FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer, including response, progression-free survival, overall survival, KRAS subgroup analyses, methodology, and…
- ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.
- ORION-10Independent statistical analysis of ORION-10, a randomized phase 3 trial of inclisiran versus placebo in participants with atherosclerotic cardiovascular disease and elevated low-density lipoprotein cholesterol, including ANCOVA results, confidence intervals, p-values, trial…
- ORION-11Complete statistical analysis of ORION-11, the randomized phase 3 trial of inclisiran in subjects with ASCVD or ASCVD-risk equivalents and elevated LDL-C, including ANCOVA methodology, primary and secondary endpoint results, confidence intervals,…
- PACIFICComplete statistical analysis of the PACIFIC phase 3 trial of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer, including primary endpoints, time-to-event methods, secondary analyses, safety,…
- PALLASIndependent statistical analysis of PALLAS (NCT02513394), a randomized phase 3 trial of palbociclib plus standard adjuvant endocrine therapy versus endocrine therapy alone in HR+/HER2- invasive early breast cancer.
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- PAPILLONIndependent statistical analysis of the phase 3 PAPILLON trial of amivantamab plus chemotherapy versus chemotherapy alone in advanced or metastatic non-small cell lung cancer characterized by EGFR exon 20 insertions.
- PARAGON-HFIndependent statistical analysis of PARAGON-HF, evaluating LCZ696 versus valsartan in heart failure with preserved ejection fraction, including primary and secondary endpoint analyses, statistical methods, interpretation, and limitations.
- Partners PrEPAn independent statistical analysis of the Partners PrEP phase 3 trial, examining TDF and FTC/TDF for prevention of HIV-1 acquisition in HIV-1 discordant couples, including Cox regression, hazard ratios, safety, longitudinal analyses,…
- PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…
- PEARLSIndependent statistical analysis of the PEARLS phase 3 trial of pembrolizumab versus placebo after resection in non-small cell lung cancer, including disease-free survival, Cox regression, hazard ratios, confidence intervals, one-sided testing, and…
- PIONEER 6Independent statistical analysis of PIONEER 6, the randomized phase 3 trial of oral semaglutide versus placebo in subjects with type 2 diabetes, including its MACE endpoint, non-inferiority analysis, Cox model, hazard ratio,…
- PIONEER AF-PCIComplete statistical analysis of PIONEER AF-PCI, the randomized phase 3 trial evaluating rivaroxaban-based strategies versus vitamin K antagonist therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
- PIONEER-HFIndependent statistical analysis of PIONEER-HF, evaluating sacubitril/valsartan versus enalapril on NT-proBNP in patients stabilized after an acute heart failure episode. Includes trial design, ANCOVA methodology, reported primary and secondary results, safety, and…
- POINTComplete statistical analysis of the POINT phase 3 trial of clopidogrel versus placebo in transient ischemic attack, including trial design, 90-day efficacy and hemorrhage endpoints, hazard ratios, confidence intervals, log-rank testing, and…
- POSEIDONIndependent statistical analysis of the phase 3 POSEIDON trial of durvalumab plus tremelimumab with chemotherapy, durvalumab with chemotherapy, or chemotherapy alone in non-small cell lung cancer, including survival, response, methodology, and interpretation.
- PRESERVE 1Independent statistical analysis of PRESERVE 1, a randomized phase 3 trial of trilaciclib versus placebo with FOLFOXIRI/bevacizumab in metastatic colorectal cancer, including primary endpoint results, ANCOVA, Poisson regression, and statistical interpretation.
- PREVAILIndependent statistical analysis of the phase 3 PREVAIL trial of enzalutamide versus placebo in chemotherapy-naive patients with progressive metastatic prostate cancer, including time-to-event endpoints, response analyses, safety, and statistical interpretation.
- PROCLAIMIndependent statistical analysis of the PROCLAIM phase 3 trial, including its randomized design, overall survival analysis, progression-free survival, response, relapse patterns, swallowing outcomes, safety, statistical methods, and interpretation.
- PRoFESSAn independent statistical analysis of PRoFESS (NCT00153062), including its randomized double-blind design, recurrent-stroke endpoints, Cox proportional-hazards analyses, non-inferiority framework, hazard ratios, confidence intervals, and secondary outcomes.
- PROFILE 1014Independent statistical analysis of PROFILE 1014, evaluating crizotinib versus pemetrexed plus cisplatin or carboplatin in ALK-positive non-squamous lung cancer, with detailed interpretation of progression-free survival, overall survival, response, patient-reported outcomes, and statistical…
- PROfoundIndependent statistical analysis of the PROfound phase 3 trial of olaparib versus investigators' choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer, including trial design, time-to-event and response…
- PROMISE-2Independent statistical analysis of the PROMISE-2 phase 3 trial of ALD403 (eptinezumab) for the prevention of chronic migraine, including trial design, endpoints, ANCOVA, MMRM, Cochran-Mantel-Haenszel analyses, reported results, safety, and statistical interpretation.
- PROpelIndependent statistical analysis of the PROpel phase 3 trial of olaparib plus abiraterone in men with metastatic castration-resistant prostate cancer, including randomized trial design, radiological progression-free survival, overall survival, secondary time-to-event endpoints,…
- PROSPERIndependent statistical analysis of the phase 3 PROSPER trial of enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer, including metastasis-free survival, secondary time-to-event endpoints, PSA response, statistical methodology, and interpretation.
- PURPOSE 2Independent statistical analysis of PURPOSE 2, a randomized phase 3 trial of lenacapavir for HIV pre-exposure prophylaxis, including its rate-based primary analyses, Poisson regression, Wald testing, confidence intervals, and statistical interpretation.
- QUAZAR AML-001Independent statistical analysis of QUAZAR AML-001, a randomized phase 3 trial of oral azacitidine plus best supportive care versus placebo plus best supportive care as maintenance therapy in acute myeloid leukemia in…
- RAINBOWIndependent statistical analysis of the phase 3 RAINBOW trial of ramucirumab plus paclitaxel versus placebo plus paclitaxel in metastatic gastric adenocarcinoma, including survival, response, quality-of-life, safety, and statistical methodology.
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RATIONALE-303Independent statistical analysis of RATIONALE-303, a randomized phase 3 trial comparing tislelizumab with docetaxel in second- or third-line non-small cell lung cancer, including overall survival, response, progression-free survival, quality of life, and…
- RE-COVER IIIndependent statistical analysis of RE-COVER II, a randomized phase 3 trial comparing dabigatran etexilate with warfarin for treatment of acute symptomatic venous thromboembolism, including non-inferiority and time-to-event analyses.
- RE-LYComplete statistical analysis of the RE-LY phase 3 trial of dabigatran versus warfarin, including randomized trial design, time-to-event endpoints, Cox proportional-hazards analyses, non-inferiority and superiority comparisons, safety, and statistical interpretation.
- RE-MODELComplete statistical analysis of the RE-MODEL phase 3 trial of dabigatran etexilate versus enoxaparin for prevention of thrombosis after knee surgery, including non-inferiority methodology, risk differences, confidence intervals, secondary endpoints, and safety.
- RE-NOVATEIndependent statistical analysis of the RE-NOVATE phase 3 trial comparing dabigatran etexilate with enoxaparin for prevention of venous thromboembolism following total hip arthroplasty.
- RE-SPECT ESUSIndependent statistical analysis of RE-SPECT ESUS, the randomized phase 3 trial of dabigatran etexilate versus aspirin for secondary stroke prevention after embolic stroke of undetermined source. Includes trial design, time-to-event endpoints, Cox…
- REACHIndependent statistical analysis of the phase 3 REACH trial of ramucirumab plus best supportive care versus placebo plus best supportive care as second-line treatment for hepatocellular carcinoma after sorafenib.
- REACH-2Independent statistical analysis of REACH-2, a randomized phase 3 trial of ramucirumab plus best supportive care versus placebo plus best supportive care in hepatocellular carcinoma with elevated baseline alpha-fetoprotein.
- REACTComplete statistical analysis of the REACT trial (NCT01329029), evaluating roflumilast versus placebo in patients with chronic obstructive pulmonary disease treated with fixed LABA and inhaled glucocorticosteroid combinations.
- RECOURSEIndependent statistical analysis of the phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies, including trial design, time-to-event endpoints, hazard ratios, confidence intervals,…
- RED-HFIndependent statistical analysis of the RED-HF phase 3 trial of darbepoetin alfa in heart failure, including trial design, time-to-event endpoints, hazard ratios, KCCQ analyses, safety, methodology, and statistical interpretation.
- REDUCE-ITComplete statistical analysis of REDUCE-IT (NCT01492361), a randomized phase 3 trial of AMR101 versus placebo in high-risk patients with cardiovascular disease and hypertriglyceridemia on statin therapy.
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- RESORCEIndependent statistical analysis of the phase 3 RESORCE trial of regorafenib versus placebo in hepatocellular carcinoma, including overall survival, time to progression, progression-free survival, tumor response, statistical methodology, and interpretation.
- RESPIRE 1Independent statistical analysis of RESPIRE 1, a randomized phase 3 trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis, including time-to-exacerbation and exacerbation-rate analyses.